Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery

Essentials Recombinant von Willebrand factor (rVWF) is effective in von Willebrand disease (VWD). A phase 3 study of rVWF, with/without recombinant factor VIII (rFVIII) before surgery in VWD. Overall rVWF's efficacy was rated excellent/good; rVWF was administered alone in most patients. rVWF was well‐tolerated and hemostasis was achieved in patients with severe VWD undergoing surgery.

[1]  W. Miesbach.  Phase 3 study of recombinant von Willebrand factor in patients with severe von Willebrand disease who are undergoing elective surgery: Comment , 2019, Journal of thrombosis and haemostasis : JTH.

[2]  P. Mannucci,et al.  Laboratory monitoring of replacement therapy for major surgery in von Willebrand disease , 2017, Haemophilia : the official journal of the World Federation of Hemophilia.

[3]  W. Miesbach,et al.  Von Willebrand disease – the ‘Dos’ and ‘Don'ts’ in surgery , 2017, European journal of haematology.

[4]  P. Kouides,et al.  Recombinant von Willebrand factor: a first-of-its-kind product for von Willebrand disease. , 2016, Drugs of today.

[5]  J. Eikenboom,et al.  Von Willebrand's Disease. , 2016, The New England journal of medicine.

[6]  M. Franchini,et al.  Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease , 2016, Expert review of hematology.

[7]  J. Gill,et al.  Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. , 2015, Blood.

[8]  Zong-ke Zhou,et al.  Risk factors for venous thromboembolism of total hip arthroplasty and total knee arthroplasty: a systematic review of evidences in ten years , 2015, BMC Musculoskeletal Disorders.

[9]  A. Reininger.  The function of ultra-large von Willebrand factor multimers in high shear flow controlled by ADAMTS13 , 2015, Hämostaseologie.

[10]  P. Mannucci,et al.  Thromboembolic incidence with transiently elevated levels of coagulation factors in patients with von Willebrand disease treated with VWF:FVIII concentrate during surgery , 2014, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  R. Schneppenheim,et al.  Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis , 2014, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[12]  C. Kempton,et al.  Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. , 2013, Blood.

[13]  J. Eikenboom,et al.  Principles of care for the diagnosis and treatment of von Willebrand disease , 2013, Haematologica.

[14]  Keishu Yasuda,et al.  Deep vein thrombosis in orthopedic surgery of the lower extremities. , 2012, Annals of vascular diseases.

[15]  H. Ehrlich,et al.  Development of a plasma- and albumin -free recombinant von Willebrand factor , 2009, Hämostaseologie.

[16]  J. Batlle,et al.  Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease , 2009, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[17]  P. Mannucci,et al.  Treatment of severe von Willebrand disease with a high‐purity von Willebrand factor concentrate (Wilfactin®): a prospective study of 50 patients , 2007, Journal of thrombosis and haemostasis : JTH.

[18]  H. Metzner,et al.  Comparative Analysis and Classification of von Willebrand Factor/Factor VIII Concentrates: Impact on Treatment of Patients with von Willebrand Disease , 2006, Seminars in thrombosis and hemostasis.

[19]  A. Turpie,et al.  Deep‐vein thrombosis rates after major orthopedic surgery in Asia. An epidemiological study based on postoperative screening with centrally adjudicated bilateral venography , 2005, Journal of thrombosis and haemostasis : JTH.

[20]  P. Mannucci.  Treatment of von Willebrand's Disease. , 2004, The New England journal of medicine.

[21]  D. Schroeder,et al.  Risk Factors for Clinically Relevant Pulmonary Embolism and Deep Venous Thrombosis in Patients Undergoing Primary Hip or Knee Arthroplasty , 2003, Anesthesiology.

[22]  P. Mannucci.  Treatment of von Willebrand Disease. , 1998, Hematology.

[23]  M. Furlan,et al.  Von Willebrand factor: molecular size and functional activity , 1996, Annals of Hematology.